An insight into the early mechanisms of allergen-specific immunotherapy

被引:4
|
作者
Mitsias, Dimitris I. [1 ]
Savvatianos, Savvas [1 ]
Papadopoulos, Nikolaos G. [1 ]
机构
[1] Univ Athens, Dept Allergy, Pediat Clin 2, Athens, Greece
关键词
allergen-specific immunotherapy; apoptosis; desensitization; IDO; indoleamine 2,3-dioxygenase; inhibitory receptor; leukocyte immunoglobulin-like receptor; LILR; rush protocol; tolerance; tryptophan starvation; venom; INHIBITORY RECEPTORS ILT3; T-REGULATORY CELLS; POLLEN IMMUNOTHERAPY; VENOM IMMUNOTHERAPY; IMMUNE DEVIATION; DENDRITIC CELLS; INDUCTION; RESPONSES; DESENSITIZATION; ACTIVATION;
D O I
10.2217/IMT.10.112
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Evaluation of: Bussmann C, Xia J, Allam J-P, Maintz L, Bieber T, Novak N: Early markers for protective mechanisms during rush venom immunotherapy. Allergy 65, 1558-1565(2010). The mechanisms governing the induction of peripheral tolerance as a result of specific immunotherapy are far from being clearly characterized. In the last 15 years, a number of studies have highlighted the tolerogenic role of regulatory T cells, blocking antibodies and anti-inflammatory cytokines such as IL-10 and TGF-beta; however, the best part of our knowledge is mostly limited to mechanisms underlying the maintenance phase. By contrast, little is known regarding the very early effects seen in rush and ultrarush immunotherapy protocols. In this article, Bussmann et al. provide evidence on the possible role, first, of inhibitory receptors of the leukocyte immunoglobulin-like receptor family and, second, of the upregulation of indoleamine 2,3-dioxygenase and subsequent tryptophan starvation on the induction of specific tolerance within a few hours after the initial doses. They also suggest that the observed changes reflect the activation of protective mechanisms, which we are just beginning to understand.
引用
下载
收藏
页码:333 / 336
页数:4
相关论文
共 50 条
  • [31] Allergen-specific immunotherapy in children
    Maslany, Anna
    Jung, Anna
    PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2011, 7 (03): : 212 - 217
  • [32] Allergen-specific immunotherapy in Kazakhstan
    Ispayeva, Z.
    ALLERGY, 2012, 67 : 521 - 521
  • [33] Allergen-specific immunotherapy or desensitization
    Demoly, Pascal
    Michel, Francois-Bernard
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2009, 193 (05): : 1127 - 1144
  • [34] The Future of Allergen-Specific Immunotherapy
    Jutel, Marek
    Solarewicz-Madejek, Katarzyna
    Smolinska, Sylwia
    DRUG INFORMATION JOURNAL, 2012, 46 (06): : 683 - 687
  • [35] Intralymphatic allergen-specific immunotherapy
    Kang, Sung-Moon
    Jung, Joo Hyun
    Lee, Sang Min
    Lee, Sang Pyo
    ALLERGY ASTHMA & RESPIRATORY DISEASE, 2020, 8 (02): : 53 - 65
  • [36] Advances in allergen-specific immunotherapy
    Verhagen, J
    Taylor, A
    Akdis, CA
    Akdis, M
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (04) : 537 - 544
  • [37] Future of allergen-specific Immunotherapy
    Novak, N.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 : 81 - 81
  • [38] Allergen-specific immunotherapy in children
    El-Sayed, Zeinab A.
    El-Farghali, Ola G.
    EGYPTIAN JOURNAL OF PEDIATRIC ALLERGY AND IMMUNOLOGY, 2012, 10 (02): : 55 - 66
  • [39] Allergen-specific immunotherapy Regulatory T cells or allergen-specific IgG?
    Kuendig, Thomas M.
    Bachmann, Martin F.
    HUMAN VACCINES, 2010, 6 (08): : 673 - 675
  • [40] The Future of Allergen-Specific Immunotherapy
    Marek Jutel
    Katarzyna Solarewicz-Madejek
    Sylwia Smolińska
    Drug information journal : DIJ / Drug Information Association, 2012, 46 : 683 - 687